Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

NVAX stock hub

Novavax, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NVAXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.7B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

NVAX

In the news

Latest news · NVAX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC15.3

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NVAX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

224

Groups with data

Currency

USD

Showing 224 of 224 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001000694
Company name	Novavax, Inc.
Country	United States
Country code	US
Cusip	670002401
Employees	749
Employees Change	-203%
Employees Change Percent	-21.32
Enterprise value	$1.2B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	1995-12-05
Isin	US6700024010
Last refreshed	2026-05-10
Market cap	$1.7B
Market cap category	Small-Cap
Price	$10.11
Price currency	USD
Rev Per Employee	796,178.91x
Sector	Healthcare
Sic	2836
Symbol	NVAX
Website	https://www.novavax.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-5.28%
EV Sales Forward	3.09x
EV/EBIT	31.38x
EV/EBITDA	19.61x
EV/Sales	1.96x
FCF yield	-5.82%
P/S ratio	2.79x
PS Forward	4.41x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	6.24%
EBITDA Margin	9.98%
Gross margin	27.49%
Gross Profit	$164M
Gross Profit Growth	-77.38%
Gross Profit Growth Q	-95.3%
Net Income	$-87.8M
Net Income Growth Years	4%
Pretax Margin	-14.45%
Profit Margin	-14.73%
Profit Per Employee	$-117,270
Profitable Years	1
ROA	1.99
Roa5y	-13.46
ROCE	5.31
ROIC	15.33

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-19.83%
Cagr15y	-9.69%
Cagr1y	69.98%
Cagr20y	-11.61%
Cagr3y	9.45%
Cagr5y	-43.53%
EPS Growth Years	4
Revenue Growth	-52.48x
Revenue Growth Q	-79.07x
Revenue Growth Years	1x
Revenue Growth3 Y	-24.01x
Revenue Growth5 Y	-8.3x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.51
Assets	$1B
Cash	$790.3M
Current Assets	$850.8M
Current Liabilities	$342.5M
Debt	$295.1M
Debt EBITDA	$4.34
Equity	$-144.8M
Interest Coverage	1.65
Liabilities	$1.2B
Long Term Assets	$192.3M
Long Term Liabilities	$845.5M
Net Cash	$495.3M
Net Cash By Market Cap	$29.79
Net Cash Growth	-1.5%
Net Debt EBITDA	$-8.32
Tangible Book Value	$-257.6M
Tangible Book Value Per Share	$-1.57
WACC	15.58

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.48
Inventory Turnover	39.81
Net Working Capital	$-279.9M
Quick ratio	2.38
Working Capital	$508.4M
Working Capital Turnover	$1.25

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.58%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-89.03%
1Y total return	69.92%
200-day SMA	8.24
3Y total return	31.13%
50-day SMA	9.01
50-day SMA vs 200-day SMA	50over200
5Y total return	-94.26%
All Time High	331.7
All Time High Change	-96.95%
All Time High Date	2021-02-09
All Time Low	3.53
All Time Low Change	186.24%
All Time Low Date	2024-02-05
ATR	0.57
Beta	2.37
Beta1y	2.03
Beta2y	1.75
Ch YTD	50.45
High	10.75
High52	11.97
High52 Date	2026-02-26
High52ch	-15.54%
Low	9.32
Low52	5.8
Low52 Date	2025-05-09
Low52ch	74.31%
Ma50ch	12.25%
Premarket Change Percent	1.19
Premarket Price	$9.34
Premarket Volume	100,354
Price vs 200-day SMA	22.71%
RSI	70.42
RSI Monthly	47.27
RSI Weekly	59.58
Sharpe ratio	1.04x
Sortino ratio	1.9
Total Return	-0.58%
Tr YTD	50.45
Tr15y	-78.3%
Tr1m	26.69%
Tr1w	25.75%
Tr3m	22.55%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	10
Analyst Count Top	3
Analyst Price Target Top	$9.33
Analyst Ratings	Hold
Analyst Ratings Top	Hold
Earnings EPS Estimate	$-0.23
Earnings Revenue Estimate	76,867,304x
Earnings Revenue Estimate Growth	-88.47x
Operating Income	$37.2M
Operating Income Growth	-91.2
Operating margin	6.24
Price target	$11.1
Price Target Change	$9.79
Price Target Change Top	$-7.72

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	141,464,301%
Float Percent	86.03%
Net Borrowing	80,569,000
Shares Insiders	0.84%
Shares Institutions	57.96%
Shares Out	164,438,119
Shares Qo Q	-1.15%
Shares Yo Y	0.58%
Short Float	32.76%
Short Ratio	12.37
Short Shares	28.18

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-130.2M
Average Volume	4,479,848x
Bv Per Share	-0.88
CAPEX	$-5.2M
Ch10y	-89.03
Ch15y	-78.3
Ch1m	26.69
Ch1w	25.75
Ch1y	69.92
Ch20y	-91.53
Ch3m	22.55
Ch3y	31.13
Ch5y	-94.26
Ch6m	35.89
Change	9.53%
Change From Open	8.01
Close	9.23
Days Gap	1.41
Depreciation Amortization	22,335,000
Dollar Volume	135,009,395
Earnings Date	2026-05-06
Earnings Time	bmo
EBIT	$37.2M
EBITDA	$59.5M
EPS	$-0.54
F Score	2
FCF	$-96.8M
FCF EV Yield	-8.29x
FCF Per Share	$-0.59
Financing CF	72,473,000
Fiscal Year End	December
Founded	1,987
Goodwill	112,888,000
Income Tax	$1.7M
Investing CF	-33,309,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Date	2019-05-10
Last Split Type	Reverse
Last10k Filing Date	2026-02-26
Ma150	8.28
Ma150ch	22.06%
Ma20	8.47
Ma20ch	19.36%
Net CF	-45,555,000
Next Earnings Date	2026-08-05
Open	9.36
Optionable	Yes
Position In Range	55.24
Post Close	10.11
Postmarket Change Percent	2.08
Postmarket Price	$10.32
Ppne	63,507,000
Pre Close	9.23
Price Date	2026-05-08
Price EBITDA	$27.93
Relative Volume	2.98x
Revenue	596,338,000x
SBC By Revenue	5.61x
Share Based Comp	33,454,000
Tax By Revenue	0.28x
Tr20y	-91.53%
Tr6m	35.89%
Us State	Maryland
Views	87
Volume	13,354,045
Z Score	-4.23

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does NVAX pay a dividend?

Capital-return profile for this ticker.

Performance

NVAX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NVAX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+58.0%

Float: +86.0% of shares outstanding

Insider ownership

+0.8%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

NVAX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

70.4

Above 70: short-term overbought

Price vs 200-day MA

+22.7%

50/200-day relationship not available

Beta (5Y)

2.37

More volatile than the market

Sharpe ratio

1.04

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NVAX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current NVAX stock rating?

Novavax, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full NVAX analysis?

The full report lives at /stocks/NVAX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for NVAX?

The latest report frames NVAX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the NVAX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.